



Setting a New Standard in Eyewear.



PATENTED
NANOTECH IP



LARGE
ADDRESSABLE
MARKET



FDA-REGISTERED
CLASS 1 DEVICE

Disclaimer

Forward-Looking Information This document contains forward looking statements, including Future Oriented Financial Information (“FOFI”) that relate to our current expectations and views of future events. Certain information contained herein and certain made are forward-looking and relate to RISE NANO OPTICS Ltd.’s (“RISE” or the “Company”) business strategy, any estimate of potential earnings, the completion of any transaction including contracts with potential customers, expected growth in the global market, acquisition of additional facilities, product development, timing of product development, events, courses of action, the proposed transaction with FTC Cards Inc. (“FTC”) and related financing, regulatory approvals and other matters. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to”, “project”, “continue” or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated cash needs and our estimates regarding our capital requirements and our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing products; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate.

The forward-looking statements has been prepared by our management to provide an outlook of our activities and results and may not be appropriate for other purposes. Our management believes that the forward-looking statements has been prepared on a reasonable basis, reflecting management’s best estimates and judgments. An investor should read this document with the understanding that our actual future results may be materially different from what we expect. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which RISE will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, the Company’s ability to complete any contemplated transactions, and that there will be no regulation or law that will prevent the Company from operating its business. Although RISE believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements.

The securities of RISE are considered highly speculative due to the nature of RISE’s business. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely affect our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; market conditions and the demand and pricing for our products; security threats; our relationships with our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; and our dependence on key personnel. RISE is an early-stage company with a short operating history, and it may not actually achieve its plans, projections, or expectations.

Important factors that could cause actual results to differ materially from RISE’s expectations include, consumer sentiment towards RISE’s products, litigation, global economic climate, the impact of Covid-19 or other viruses and diseases on the RISE’s ability to operate, equipment failures, increase in operating costs, security threats, consumer interest and sentiment in RISE’s products, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, and failure of counterparties to perform their contractual obligations. RISE’s products have yet to be produced on a large scale and its products have yet to be shown effective and reliable when used by a broad range of consumers.

Except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation.

This document is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. It does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained herein.

Market & Industry Data The information contained herein includes market and industry data that has been obtained from third party sources, including industry publications. RISE believes that its industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, RISE has not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources.


Investment Highlights

Rise is redefining the optical lens market with SpectraGuard™, a patented nano particle optical lens treatment that sets a new standard of eye protection.

We scale by selling to existing lens manufacturers, 3rd party optical labs, eyewear brands, DTC eyewear businesses, eye care professionals, and a limited number of acquisitions that will accelerate revenue generation and product adoption.



The \$160B global eyewear and eyecare market is expected to grow to \$330 billion by 2034.



The current UVA/UVB standard only protects wearers from the non-visible light spectrum.



FDA-REGISTERED
CLASS 1 DEVICE

SpectraGuard is the only lens treatment filtering UV and up to 90% of HEV between 400-600nm without becoming too dark.



PATENTED
NANOTECH IP

Seven patents protect our nano material, its production, and its application to lenses.

ONE TECHNOLOGY,
MULTIPLE MARKETS

SpectraGuard

ULTIMATE LIGHT PROTECTION



ULTIMATE
ROADTRIP
×
ULTIMATE
PROTECTION

Performance Sunglasses

Global Sunglasses Market Valued At USD \$43.03 Billion In 2025

Market Projected To Reach USD \$111.61 Billion By 2033

North America Accounted For 31% Of 2025 Global Revenue

Premium Offerings Above USD \$150 Accounted For 62% Of Sales

SpectraGuard provides superior sun protection
for any outdoor sport or activity.



SpectraGuard

ULTIMATE LIGHT PROTECTION

ULTIMATE
GAMING
×
ULTIMATE
PROTECTION

Blue Light Glasses

Blue Light Glasses Market Valued At USD \$3.0 Billion In 2025

Market Projected To Reach USD \$6.4 Billion By 2035

Key Growth Regions include: North America, Asia-Pacific, Europe

58% of Blue Light Glasses Are Prescription

SpectraGuard Photochromic combines broader protection from indoor blue light and superior sun protection for a wear-everywhere solution.

SpectraGuard
ULTIMATE LIGHT PROTECTION

ULTIMATE
SENSITIVITY
×
ULTIMATE
PROTECTION

Light Sensitivity & Photophobia

Migraine Sufferers – 1 Billion People Worldwide

Light Sensitivity (Photophobia) affects 80% of people with Migraines

Dry Eye Sufferers – 344 Million Worldwide

Light Sensitivity (Photophobia) affects 75% of people with DED

SpectraGuard can help those that suffer from light sensitivity and photophobia to experience the world with more comfort.



SpectraGuard

ULTIMATE LIGHT PROTECTION

ULTIMATE
NEED
×
ULTIMATE
PROTECTION

Degenerative Eye Disease Management

Diabetic Retinopathy – 100 Million People Worldwide

Macular Degeneration – 200 Million Worldwide

Cataracts – 100 Million Worldwide

SpectraGuard can replace and outperform dozens of various lenses used to support patients with degenerative eye disease.



450nm

- Night Blindness
- Macular Degeneration
- Pre-operative Cataract



500nm

- Macular Degeneration
- Pre-operative Cataract



540nm

- Macular Degeneration
- Pre-operative Cataract



480nm

- Macular Degeneration
- Pre-operative Cataract



550nm

- Pre-operative Cataract



600nm

- Color Blindness
- Night vision adaption



550nm

- Eye Strain
- Headaches
- Migraine



600nm


- Photosensitive Epilepsy
- Photophobia

A PATENTED SCIENTIFIC BREAKTHROUGH

Game Changing Nanotechnology

Rise's patented process imparts unique properties to an aniline polymer complex producing nano-sized particles that can be integrated into the lens substrate of lenses manufactured by world's largest lens manufacturers. Unlike traditional lens dyes, our process results in a treatment that does not scratch or wear off.

With limited capital investment and just a few weeks of training, any optical laboratory in the world can create SpectraGuard™ treated lenses.




Advanced Light Filtering

SpectraGuard
ULTIMATE LIGHT PROTECTION

UV + 400–600nm

SpectraGuard is the only lens treatment capable of filtering 100% UVA/UVB/UVC light and up to 90%+ of visible high-energy wavelengths between 400-600 nm producing sun and photochromic lenses with more comprehensive protection for consumers' eyes.


SpectraGuard Filtering on MR8 Lens Substrate




On MR8 Lens

Reduces Glare, Improves Contrast

Because of our nano material's unique properties, SpectraGuard lenses start filtering 100% of side light at a 25-degree angle of incident versus competitors at 40-degrees. By filtering problematic light earlier, consumers can experience less side glare, fewer brightness spikes, more consistent vision during movement, better performance in wrap and curved lenses, higher contrast, and an overall more comfortable experience.



AOI Of Treated vs. Un-Treated Lens




Positive Impact Shown In Peer-Reviewed Study

Conducted at The Technion – Israel Institute of Technology using diabetic rats.


In a healthy eye, Müller cells stabilize and nourish the retina, playing a critical role in vision quality.

GFAP, a marker of cellular stress, appearing in Müller cells signals cellular stress or retinal injury, indicating the eye is responding to damage.

The study findings suggest that glasses attenuating light exposure and filtering out short wavelengths (400–530 nm) may be beneficial for diabetic patients and that further study is warranted.



Without SpectraGuard™



With SpectraGuard™

Strong Patent Protection

| Patent | Status | Country & Date |
|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Method and a system for protection of retina from a light induced damage | Medical Patent (Licensed from the Technion Institute of Technology of Israel) GRANTED | USA & India No. 8833937 (USA) 16-Sep-2014 No. 316658 (INDIA) 23-Jul-2019 |
| Products using gold and silver nanoparticles and ions absorb visible and UV light | GRANTED | USA No. 12,383,955 Issue Date: 12-Aug-2025 |
| Products using gold and silver nanoparticles and ions absorb visible and UV light | National Phase Pending | EUROPE No. 3768280 Publication Date: 27-Jan-2021 |
| Diffusion of Nanoparticles into transparent plastic | GRANTED | USA No. 11,994,755 Issue Date: 28-May-2024 |
| Diffusion of Nanoparticles into transparent plastic | GRANTED | USA No. 12,147,093 Issue Date: 19-Nov-2024 |
| Diffusion of Nanoparticles into transparent plastic | National Phase Pending | EUROPE No. 4423567 Publication Date: 04-Sep-2024 |
| Aniline-based material for optical filtering and coating of optical elements | Provisional | USA 63/887,574 Publication Date: 25-Sep-2025 |

A LOW CAPEX GTM

Commercial Revenue Streams

Our Revenue Streams Don't Just Generate Revenue — They Generate Demand.

Partner Lab & Lens Manufacturer Licensing

SpectraGuard Licensed To Leading Independent And Global Labs/Manufacturers.

Revenue Streams

- Royalty Fee Per Pair
- SpectraGuard Nano Material Supply

Strategic Advantage

- Co-Branded Model Similar to Transitions Lenses
- Scales Globally Without Heavy Capex
- Builds Massive Availability Network
- Creates Long-tail Recurring Revenue
- Leverages Partner's Sales & Marketing Efforts

DTC Eyewear Licensing

SpectraGuard Licensed To Large Volume DTC Eyewear Players (e.g. GlassesUSA, Warby, Kitts).

Revenue Streams

- Royalty Fee Per Pair
- SpectraGuard Nano Material Supply

Strategic Advantage

- Co-Branded Model Similar to Transitions Lenses
- Scales Globally Without Heavy Capex
- Builds Massive Availability Network
- Creates Long-tail Recurring Revenue
- Leverages Partner's Sales & Marketing Efforts

Rise-Owned Optical Labs & Eye Care Professional Sales

Acquire 3 Fully Owned Optical Labs

- West Coast
- East Coast
- Central/Midwest

What Labs Deliver

- Fully Finished Rx Eyewear w/SpectraGuard
- B2B Sales to ECPs, Wholesalers, Clinics, Mass Merchants/Gen. Retailers

Strategic Advantage

- Builds Credibility
- Captures More of the Value Chain
- Direct Relationship w/ Prescribing ECPs
- Full Brand Control
- Rapid iteration/application of new nano-coatings

A Capital-Efficient GTM Fuelled by B2B Marketing

Strong B2B marketing drives lab adoption and ECP demand — with compelling margins and superior protection as the foundation, every dollar of spend works harder.

Our partnership-first approach allows us to build significant production and distribution capabilities with very low capital expenditures allowing us to focus expenditures on B2B sales and marketing




B2B marketing is the engine — low capex is the advantage

Closing lab deals and building ECP demand requires targeted B2B marketing investment — already baked into our financials. Competition is established, but with SpectraGuard's technology and margin story, every dollar works harder.




No big consumer spend — ECPs are the sales team

With 80% of sales happening in brick-and-mortar optical retail, the ECP is the brand advocate and consumer salesperson. Broad consumer advertising, as seen from Transitions lenses, won't be necessary for some time.



Traction validates the model. First lab signed. Multiple global labs and manufacturers in active discussions. Commercial reaction to technology and pricing has been strong.

Key Go To Market (GTM) Markets



North America

High and rising prevalence of chronic retinal disease.
Strong clinical acceptance of specialty and therapeutic lenses.
Defined regulatory framework for optical devices.

EU Japan GCC

Large elderly population drives MD and cataract demand.
High prevalence of vision correction and optical device usage.
High levels of sun exposure.


Primary Near-Term US & EU Sales Channels

INDEPENDENT ECPS

OPTICAL CHAINS




The United States has 43,773 retail optical locations
Independent practices make up 58% of locations



Source: The Vision Council's inSights Research

Every location in the United States



Primary Short to Mid-Term US & EU Sales Channels



ECP Awareness and Demand Generation

Trade Media: Integrated Print and Digital Media Campaign



Rise will leverage print, web, email, digital newsletter, and video advertising opportunities as well as outreach to each publication's editorial staff to promote SpectraGuard.

ECP Awareness and Demand Generation


ECP Sales Enablement




In-Store Signage



Tri-Fold Brochure
ECP & Consumer Versions



Web, Social, & Email Assets



Whitepapers & Technical Documents

COMPELLING FINANCIALS

Financial Summary

| 4/24/2026 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---------------------------------|--------------|--------------|--------------|---------------|---------------|
| Total Revenues | \$ 574,368 | \$ 3,839,990 | \$ 8,973,720 | \$ 14,307,690 | \$ 21,218,135 |
| COGS | \$ 245,400 | \$ 1,385,125 | \$ 2,942,000 | \$ 4,395,000 | \$ 6,044,500 |
| Gross Profit | \$ 328,968 | \$ 2,454,865 | \$ 6,031,720 | \$ 9,912,690 | \$ 15,173,635 |
| Gross Profit Margin | 57% | 64% | 67% | 69% | 72% |
| Operating Expenses | | | | | |
| R&D | \$ 246,978 | \$ 383,999 | \$ 385,870 | \$ 400,615 | \$ 424,363 |
| Sales & Marketing | \$ 344,621 | \$ 1,459,196 | \$ 2,333,167 | \$ 3,004,615 | \$ 3,394,902 |
| G&A | \$ 402,058 | \$ 575,999 | \$ 897,372 | \$ 1,144,615 | \$ 1,697,451 |
| Lab Operating Overhead | \$ 59,173 | \$ 320,138 | \$ 665,826 | \$ 757,520 | \$ 832,591 |
| Total Operating Expenses | \$ 1,052,830 | \$ 2,739,331 | \$ 4,282,235 | \$ 5,307,366 | \$ 6,349,306 |
| EBITDA | \$ (723,862) | \$ (284,466) | \$ 1,749,485 | \$ 4,605,324 | \$ 8,824,329 |
| EBITDA Margin | -126% | -7% | 19% | 32% | 42% |
| Depreciation | \$ 12,000 | \$ 42,000 | \$ 96,000 | \$ 168,000 | \$ 252,000 |
| EBIT | \$ (735,862) | \$ (326,466) | \$ 1,653,485 | \$ 4,437,324 | \$ 8,572,329 |
| EBIT Margin | -128% | -9% | 18% | 31% | 40% |

Pro Forma Cap Table

- Go Public Q1 2026
- CSE under “EYE”
- RTO Financing Round:~C\$4.0M
(Complete)

| Rise Nano Optics Ltd | |
|----------------------|-------------------|
| Common Shares | 40,374,904 |
| Warrants | 11,255,646 |
| Contingent Rights | 9,331,785 |
| Options | 456,308 |
| RSUs | 4,053,825 |
| Fully Diluted | 65,472,468 |

Escrow Terms

- ~85% of shares are locked up and cannot be sold below the listing price for one year
- ~34% Escrowed common shares follow standard CSE escrow release schedule

WINNING LEADERSHIP

Experienced Leadership

Backed by a team of industry leaders and experts in the medical field with proven track record of delivery and success

DR. INAS SAID



**Founder
& CEO**

- M.Sc. EE, IEMBA, DBA
 - Entrepreneur & executive with 25 years of experience
 - Co-Founder of Galil Software,
 - Co-Founder of Amwal Financial Services
 - Co-Founder of Sensai Networks

ERIK RITCHIE



**Chief Commercial
Officer**

- CEO, EnChroma
- CCO, Zenni Optical
- CCO, QIND CBD
- Partner, Salt Branding

DR. Awad Shalabny



**Chief Technology
Officer**

- Ph.D. , nanotechnology, BGU
- Researcher and expert in the area of nanotechnology, Process Design for Surface Modification of Nanomaterial.
- Several y7ears of industry experience in R&D and process design

GABI KABAZO



**Chief Financial
Officer**

- CPA, MBA
- 20+ years as CFO of publicly traded companies in various industries

PROF. IDO PERLMAN



**Ph.D. – Advisory
Board Member**

- Professor, Department of Physiology & Biophysics, Faculty of Medicine, Technion

PROF. NAIM SHEHADEH



**M.D. – Advisory
Board Member**

- Professor, Bruce Rappaport Faculty of Medicine, Technion
- Director, Institute of Diabetes, Endocrinology and Metabolism and Head of the Pediatrics clinic Rambam
- President of the Israel Diabetes Association.



**Thank You For
Your Consideration**

Investor Contacts

Danielle Shortall

Corporate Communications

E: Danielle.shortall@risenanooptics.com

Erik Ritchie

Chief Commercialization Officer

E: erik.ritchie@risenanooptics.com